MVASI — Class II drug recall D-0855-2022
Terminated recall by Amgen, Inc., reported 2022-05-18, distributed nationwide. Defective container: loose crimp defect, potential loss of container integrity.
| Recall number | D-0855-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Amgen, Inc., Thousand Oaks, CA, United States |
| Recall initiated | 2022-05-02 |
| Classified | 2022-05-09 |
| Reported by FDA | 2022-05-18 |
| Terminated | 2022-12-02 |
| Distributed | Nationwide (US) |
| Countries outside the US | EG, LT |
| Quantity | 15,823 |
| Reason classes | packaging |
| NDC | 55513-0206-01 |
| Lot numbers | 09/24, 1142258, 1143196 |
Product
MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01
Reason for recall
Defective container: loose crimp defect, potential loss of container integrity.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0855-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.